SCHEMBL8682249

SCHEMBL8682249

CCOC(=O)c1ccc2c(c1)C(CCCNc1ccccn1)(CCc1ccccc1)N=N2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ HTT P42858 1/20 0.40
▸ MAPT P10636 5/20 0.37
▸ GAA P10253 3/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ALOX12 P18054 1/20 0.36
▸ ITGB1 P05556 3/20 0.36
▸ ITGB3 P05106 2/20 0.36
▸ ITGAV P06756 2/20 0.36
▸ ITGB5 P18084 1/20 0.36
▸ ITGB6 P18564 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ PPIA P62937 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ ITGA5 P08648 2/20 0.35
▸ CYP4F2 P78329 1/20 0.35
▸ CYP4A11 Q02928 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8683591 0.84 NPC1 (0.43) NPC1RAB9AHTTMAPTGAA
SCHEMBL11562843 0.72 HCAR3 (0.54) NPC1RAB9AMAPTGAAKMT2A
SCHEMBL8683588 0.71 NPC1 (0.44) NPC1RAB9AHTTMAPTGAA
SCHEMBL8682252 0.70 KDM4E (0.42) NPC1RAB9AHTTMAPTKMT2A
SCHEMBL8684069 0.67 RAB9A (0.46) NPC1RAB9AHTTMAPTGAA
SCHEMBL7377874 0.66 TOP2A (0.53) NPC1RAB9AHTTALDH1A1ALOX12
SCHEMBL14289015 0.66 ITGB3 (0.60) NPC1RAB9AHTTKMT2AMEN1
SCHEMBL15714331 0.65 TOP2A (0.52) NPC1RAB9AALDH1A1ALOX12ITGB3
SCHEMBL11954569 0.65 TOP2A (0.57) NPC1RAB9AHTTALDH1A1ITGB1
SCHEMBL16607505 0.65 ALDH1A1 (0.53) NPC1RAB9AGAAALDH1A1ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5760028-A TREATING CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, MACULAR DEGENERATION THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-06-02 — — US disclosed
Send feedback